Latest news with #StLouis
New York Times
10 minutes ago
- Sport
- New York Times
Blues 2025-26 schedule takeaways: Revenge date with Winnipeg, reunions and more
ST. LOUIS — The St. Louis Blues will welcome Vladimir Tarasenko and the Minnesota Wild to town for the regular-season opener Oct. 9 at Enterprise Center. Among the many roster changes that transpired over the offseason, Tarasenko was traded from the Red Wings to the Wild, so there will be some new faces in new places when the Blues take the ice in 2025-26. Advertisement Some others are more recent Blues players facing their former team, such as Zack Bolduc (Montreal Canadiens), Nick Leddy (San Jose Sharks) and Radek Faksa (Dallas Stars). But perhaps specific players aren't of the most interest to you — it's teams. Well, after the way the 2024-25 season wrapped up, you'll want to know that the Winnipeg Jets make their first trip to St. Louis Dec. 17. The Blues can begin to get the taste of that excruciating first-round playoff loss out of their mouths when they drop the puck on the preseason Sept. 20 against the Dallas Stars — the first of six exhibition games that were announced earlier this week. #stlblues 2025 preseason schedule: — Jeremy Rutherford (@jprutherford) July 14, 2025 And on Wednesday, the Blues got their regular-season schedule: Here's the breakdown with month-by-month takeaways … (All times in CT) 9: vs. Minnesota Wild, 7 p.m. 11: at Calgary Flames, 3 p.m. 13: at Vancouver Canucks, 6:30 p.m. 15: vs. Chicago Blackhawks, 8:30 p.m. 18: vs. Dallas Stars, 6 p.m. 21: vs. Los Angeles Kings, 7 p.m. 23: vs. Utah Mammoth, 7 p.m. 25: at Detroit Red Wings, 6 p.m. 27: at Pittsburgh Penguins, 6 p.m. 28: vs. Detroit Red Wings, 7:15 p.m. 30: vs. Vancouver Canucks, 7 p.m. 1: at Columbus Blue Jackets, 6 p.m. 3: vs. Edmonton Oilers, 7:30 p.m. 5: at Washington Capitals, 6:30 p.m. 6: at Buffalo Sabres, 6 p.m. 8: vs. Seattle Kraken, 6 p.m. 11: vs. Calgary Flames, 7 p.m. 14: vs. Philadelphia Flyers, 7 p.m. 15: vs. Vegas Golden Knights, 7 p.m. 18: at Toronto Maple Leafs, 6 p.m. 20: at Philadelphia Flyers, 6 p.m. 22: at New York Islanders, 2:30 p.m. 24: at New York Rangers, 6 p.m. 26: at New Jersey Devils, 6 p.m. 28: vs. Ottawa Senators, 3 p.m. 29: vs. Utah Mammoth, 7 p.m. 1: vs. Anaheim Ducks, 7 p.m. 4: at Boston Bruins, 6 p.m. 6: at Ottawa Senators, 6 p.m. 7: at Montreal Canadiens, 6 p.m. 9: vs. Boston Bruins, 6 p.m. 11: at Nashville Predators, 7 p.m. 12: vs. Chicago Blackhawks, 7 p.m. 15: vs. Nashville Predators, 7 p.m. 17: vs. Winnipeg Jets, 7 p.m. 18: vs. New York Rangers, 7 p.m. Advertisement 20: at Florida Panthers, 5 p.m. 22: at Tampa Bay Lightning, 6 p.m. 27: vs. Nashville Predators, 7 p.m. 29: vs. Buffalo Sabres, 7 p.m. 31: at Colorado Avalanche, 8 p.m. 2: vs. Vegas Golden Knights, 2 p.m. 3: vs. Montreal Canadiens, 3 p.m. 7: at Chicago Blackhawks, 8:30 p.m. 9: at Utah Mammoth, 8 p.m. 10: at Vegas Golden Knights, 9 p.m. 13: vs. Carolina Hurricanes, 7 p.m. 16: vs. Tampa Bay Lightning, 7 p.m. 18: at Edmonton Oilers, 7 p.m. 20: at Winnipeg Jets, 7 p.m. 23: at Dallas Stars, 7 p.m. 24: vs. Los Angeles Kings, 7 p.m. 27: vs. Dallas Stars, 7 p.m. 29: vs. Florida Panthers, 7 p.m. 31: vs. Columbus Blue Jackets, 6 p.m. 2: at Nashville Predators, 7 p.m. 4: at Dallas Stars, 8:30 p.m. 26: vs. Seattle Kraken, 7 p.m. 28: vs. New Jersey Devils, 6 p.m. 1: at Minnesota Wild, 5:30 p.m. 4: at Seattle Kraken, 9 p.m. 6: at San Jose Sharks, 9 p.m. 8: at Anaheim Ducks, 8 p.m. 10: vs. New York Islanders, 6:30 p.m. 12: at Carolina Hurricanes, 6 p.m. 13: vs. Edmonton Oilers, 7 p.m. 15: at Winnipeg Jets, 2 p.m. 18: at Calgary Flames, 8:30 p.m. 21: at Vancouver Canucks, 6 p.m. 24: vs. Washington Capitals, 7 p.m. 26: vs. San Jose Sharks, 7 p.m. 28: vs. Toronto Maple Leafs, 6 p.m. 30: at San Jose Sharks, 9 p.m. 1: at Los Angeles Kings, 8 p.m. 3: at Anaheim Ducks, 9 p.m. 5: at Colorado Avalanche, 8:30 p.m. 7: vs. Colorado Avalanche, 7 p.m. 9: vs. Winnipeg Jets, 7 p.m. 11: at Chicago Blackhawks, 4 p.m. 13: vs. Minnesota Wild, 7 p.m. 14: vs. Pittsburgh Penguins, 8:30 p.m. 16: at Utah Mammoth, 7 p.m.
E&E News
2 hours ago
- Health
- E&E News
Rollins outlines plan to expand fight against foodborne illness
Agriculture Secretary Brooke Rollins unveiled a modernized Midwestern Food Safety Laboratory in Missouri on Tuesday, at an event where she also rolled out a comprehensive plan to combat foodborne illness. The 70,000-square-foot facility near St. Louis will support new testing methods for listeria, which have resulted in a more than 200 percent increase in samples from last year, USDA said in a statement. 'USDA is charting a bold new course in giving consumers confidence their meat, poultry, and egg products meet our best-in-class food safety standards,' Rollins said in the USDA statement. 'I look forward to continued collaboration across the Trump administration, with states, and with food producers from farm to table, to reduce foodborne illness and protect public health.' Advertisement The five-pronged plan Rollins outlined includes enhancing microbiological inspection oversight; updating training for Food Safety and Inspection Service inspectors, combating salmonella illness, strengthening state partnerships, and bolstering enforcement action.
Associated Press
3 hours ago
- Business
- Associated Press
One10 Accelerates Incentive Innovation with Whistle Acquisition
MINNEAPOLIS--(BUSINESS WIRE)--Jul 16, 2025-- One10 LLC (' One10 '), a leader in performance improvement and incentive solutions, has acquired Whistle, a St. Louis-based employee engagement and rewards technology company. The acquisition significantly strengthens One10's position in behavioral science, data science and incentive technology capabilities, enabling faster, more targeted ways to improve performance across employee and channel ecosystems. Whistle, known for its award-winning technology, also brings a team with deep industry expertise, including co-founders Drew Carter and Chris Dornfeld. Whistle employees will remain in St. Louis and officially become One10 team members. 'This is a powerful moment for One10,' said Bob Miller, President and CEO of One10. 'The Whistle team brings cutting-edge talent and a platform rooted in data science, which aligns perfectly with our mission to drive results for our clients by improving the performance of their employees and channels.' Drew Carter will join One10 as President of Performance Solutions, overseeing the company's Incentive & Recognition and Marketing Services solution areas. Chris Dornfeld will become Executive Vice President of Product Strategy, leading the continued development of Whistle's technology and the next generation of One10's incentive platform. 'By joining forces with One10, we're combining Whistle's agile technology with One10's proven expertise and scale, delivering clients even more powerful ways to drive performance,' said Carter. 'This partnership expands what's possible - making it easier and faster for companies to engage employees and channel partners in meaningful, measurable ways.' The acquisition is the latest strategic move by One10 to expand its capabilities and product-led solutions. The integration of Whistle's technology, talent, and behavioral science expertise will accelerate One10's product roadmap and client value delivery. For more information, visit About One10 One10 LLC is a leader in incentives and recognition, travel and events, and marketing services across the U.S. and Canada. The company offers software solutions to enable and engage corporate employees, salespeople, and channel partners. One10's global rewards, prepaid solutions and products help some of the world's most admired brands improve engagement and drive results. One10 is backed by Bow River Capital, a private alternative asset manager based in Denver, Colorado. Bow River Capital Evergreen Fund is distributed by Foreside Financial Services, LLC, which is not affiliated with Bow River Capital or its affiliates. View source version on CONTACT: Press Contact: Mary Prevost, Prevost Partners [email protected], 612-202-3047 KEYWORD: UNITED STATES NORTH AMERICA MINNESOTA MISSOURI INDUSTRY KEYWORD: OTHER PROFESSIONAL SERVICES AUTOMOTIVE SOFTWARE HUMAN RESOURCES PROFESSIONAL SERVICES TECHNOLOGY DIGITAL MARKETING OTHER COMMUNICATIONS MARKETING ADVERTISING COMMUNICATIONS VACATION OTHER TRAVEL CRUISE GENERAL AUTOMOTIVE LODGING DESTINATIONS TRAVEL SOURCE: One10 LLC Copyright Business Wire 2025. PUB: 07/16/2025 01:19 PM/DISC: 07/16/2025 01:19 PM
Daily Mail
4 hours ago
- Climate
- Daily Mail
What FEMA's funds mean for the next disaster
Published: | After flooding hit Saint Ann and the greater St. Louis area in Missouri in 2022, Beth Gutzler received help from the Federal Emergency Management Agency (FEMA). 'Basements were flooded. I hate to say it, but that's almost become normal,' she mentioned. 'FEMA was the first person that I called,' she said. 'I have this memory of having emergency funds in my account within a week. I just have this memory of how it's supposed to be.' Currently, Gutzler is having difficulty getting any response for assistance with damages caused by a tornado that struck the St. Louis area in March, impacting her new community of Florissant. Meanwhile, others across the state are also seeking help following another tornado that hit the region in May. 'There was absolutely no response from FEMA until weeks and weeks later,' she said. 'I would assume it's administration and their capacity.' Drawing on her background in customer service, she added, 'I know what you're taught to do if people call and you can't have answers for them. You're taught to just delay.' As the Atlantic hurricane season begins in the eastern US and officials deal with with deadly flooding in Texas, FEMA is under increasing pressure, competing for limited resources amid broad federal staffing reductions. Experts are concerned that there may not be sufficient funding or personnel available when the next major disaster strikes. 'We know this is going to be an active Atlantic hurricane season,' said Shana Udvardy, senior climate resilience policy analyst with the Union of Concerned Scientists, a non-profit group. 'All we need is one big hurricane, and we're going to probably be in 'immediate needs' funding,' she said, referring to a special designation when disaster funds run low. Disaster relief fund Donald Trump has issued a disaster declaration following this month's devastating floods in Texas. This designation enables both public agencies and local residents to request federal assistance. However, the Federal Emergency Management Agency (FEMA) is already under significant financial strain due to a rising number of increasingly severe disasters. According to the latest estimates, its Disaster Relief Fund (DRF) could face a shortfall of approximately $1.6 billion to $2.3 billion by the end of September. Despite this, White House budget director Russell Vought stated that there are adequate funds available to respond to the Texas disaster. He told reporters this month that 'FEMA has $13 billion in its reserves right now to continue to pay for the necessary expenses,' adding, 'The president has said to Texas anything it needs, it will get.' Still, should the disaster fund dip too low, the government would shift to an 'immediate needs' status—prioritizing only critical emergency expenditures while postponing other projects. 'It's just adding more stress for those states and local communities that are relying on this funding to come through,' Udvardy said. FEMA declined to comment on the matter. States, municipalities, and non-profit organizations had been receiving enhanced support for disaster prevention efforts through initiatives such as the Building Resilient Infrastructure and Communities (BRIC) program. However, in April, FEMA announced the termination of BRIC, labeling the program 'wasteful' and 'politicized,' and stated that any remaining funds would be redirected to the Disaster Relief Fund. Several lawmakers in Congress have urged Trump to reinstate the program grants and are questioning whether staff reductions at FEMA and other federal agencies, such as the National Weather Service, hindered the response to the Texas flooding. The administration 'cannot ignore the fact that natural disasters are becoming more severe and more frequent due to climate change,' said Rep. Bennie Thompson of Mississippi, the ranking Democrat on the House Homeland Security Committee. 'The president threatening to eliminate FEMA, firing scientists and muzzling experts helps no one and puts us all in danger,' Thompson said. Department of Homeland Security Secretary Kristi Noem commented on FEMA saying it has been 'disastrous' and 'incompetent' in some cases throughout the years, especially after Hurricane Katrina in 2005. 'It has been slow to respond at the federal level - it's even been slower to get the resources to Americans in crisis, and that is why this entire agency needs to be eliminated as it exists today and remade into a responsive agency,' she told the FEMA Review Council. Local solutions One approach the administration might take to preserve the relief fund is by reducing the number of major disaster declarations, though this essentially transfers the burden of recovery expenses to state and local governments. 'Certainly it appears that they are much less eager to provide disaster funding post-disaster, or at least declaring a major disaster,' said Steve Ellis, president of Taxpayers for Common Sense, a watchdog group. In response to the growing frequency and severity of climate-induced storms, wildfires, and hurricanes, nonprofit organizations, along with state and local authorities, have been developing their own strategies.
Health Line
7 hours ago
- Health
- Health Line
GLP-1 Drugs May Boost Testosterone Levels In Men With Obesity, Diabetes
New research shows that GLP-1 medications are associated with improved testosterone in males with obesity or type 2 diabetes. The findings align with prior evidence showing that weight loss can support healthy testosterone levels. Obesity and type 2 diabetes are recognized as comorbidities for low testosterone and sexual dysfunction. GLP-1 medications can help improve low testosterone in males with obesity or type 2 diabetes, new research suggests. Testosterone is a key hormone involved in functions ranging from sexual health to muscle development. While various factors influence testosterone levels, obesity and type 2 diabetes are both recognized risk factors for low testosterone. Researchers have already shown that weight loss improves testosterone levels through lifestyle modifications and treatments such as bariatric surgery. GLP-1 drugs, a class of obesity and diabetes medications that includes Ozempic, Wegovy, Zepbound, and Mounjaro, are known to produce significant weight loss. However, their effects on testosterone levels hadn't yet been studied. 'We found that men treated with GLP-1–based weight loss therapies, such as semaglutide, dulaglutide, and tirzepatide, experienced significant increases in both total and free testosterone levels,' said Shellsea Portillo Canales, MD, first author of the study and endocrinologist at SSM Health St. Louis University Hospital. 'These findings suggest that in men with obesity or type 2 diabetes, incretin-based therapy may help restore healthy testosterone levels, particularly when low testosterone is related to obesity,' she told Healthline. Portillo Canales presented her research on July 14 at ENDO 2025, the Endocrine Society's annual meeting in San Francisco, California. The study has not yet been published in a peer-reviewed journal. The findings are not surprising, but they help to answer an important, unanswered question about GLP-1 drugs and sexual health. 'This preliminary study fills a nice gap in the research in this area,' said David B. Sarwer, PhD, director of the Center for Obesity Research and Education, Temple University, and a spokesperson for the Obesity Society who wasn't involved in the research. 'It adds to a rapidly growing evidence base suggesting that these medications, in addition to promoting clinically significant weight loss, also have a wide range of secondary health benefits,' he said. Testosterone levels improved in most participants Portillo Canales and her team conducted a retrospective study of people with obesity and type 2 diabetes using electronic health records to investigate the effects of GLP-1 drugs on testosterone over an 18-month period. The study included 110 males, most of whom were white and in their mid-50s. Their average body mass index (BMI) was 35, meeting the threshold for clinical obesity, and 86 had type 2 diabetes. Subjects were excluded if they had received testosterone or other androgenic therapies. At baseline, just over half of the men had total testosterone levels above 300 nanograms per deciliter (ng/dL). According to the American Urological Association, any value below this threshold indicates low testosterone. After 18 months on GLP-1 receptor agonists, the proportion of men with healthy testosterone rose to 77%. The average participant lost about 26 pounds, decreasing from 255 to 229 pounds or approximately 10% of their body weight. Concurrently, total testosterone increased by about 18% (from 322 to 380 ng/dL), while free testosterone rose by 17%. 'This tracks with what we would expect based on how weight loss affects testosterone concentrations,' said Beverly Tchang, MD, an endocrinologist and obesity medicine specialist at Weill Cornell Medicine. Tchang wasn't involved in the study. Studies consistently demonstrate that reductions in body weight correlate with increases in testosterone among men, particularly those with obesity. Other interventions that produce substantial weight loss — such as bariatric surgery — have likewise been associated with improved testosterone levels and overall hormonal balance. While there is no evidence that GLP-1 medications stimulate testosterone production directly, the increase in testosterone driven by their weight-loss effects appears comparable to that of other weight loss strategies. What is low-T (male hypogonadism)? Low testosterone (low-T) in males occurs when the testicles do not produce enough testosterone. Signs of low testosterone in men include: low sex drive (libido) decreased muscle mass erectile dysfunction lethargy/low energy increased body fat The most serious form of low-T is known as pathologic hypogonadism, and indicates a persistent reduction in testosterone levels caused by an irreversible condition. However, in many cases, testosterone levels can be corrected through both lifestyle and medical interventions. Obesity-related low testosterone is one such case. 'We know obesity is associated with 'pseudo' hypogonadism — not pathological. Obesity, due to excess adiposity, can affect the hypothalamic-pituitary-testicular axis. In essence, brain centers are lowering testosterone in obesity,' said Sun Kim, MD, an associate professor of Endocrinology at Stanford Medicine who wasn't involved in the research. In fact, obesity and low testosterone can create a sort of positive feedback loop: obesity lowers testosterone, which in turn can lead to less muscle mass, which can lead to further weight gain. 'Muscle mass is one of our biggest drivers of our metabolism. So, when you have low testosterone and you have this reduced ability to build muscle, then that slower metabolism predisposes you to more weight gain,' said Tchang. In addition to being a powerful agent for weight loss, GLP-1 drugs also have meaningful downstream effects on testosterone. Kim suggested that, given these effects, people with obesity who are considering hormone replacement therapy for low-T should first consider weight loss. 'Men with obesity with low testosterone (not due to other causes) should prioritize weight loss to increase testosterone versus taking exogenous testosterone,' she said. Can GLP-1 drugs help improve sexual health? While the findings are preliminary, experts are excited by the possibility of the role that GLP-1 medications could play in improving sexual health. 'Anecdotally, we've heard of some people coming back, men specifically, saying that GLP-1s have helped their libido and sexual performance,' Tchang said. 'If these drugs have an added benefit on the testosterone side, along with healthier blood vessels or more blood flow, then we're looking at a medication that's really starting to become a sexual health aid as well.' Sarwer told Healthline that this latest study adds evidence of yet another health benefit from GLP-1 drugs. 'Over the past several years, we have seen a great deal of enthusiasm about the use of incretin therapies to promote weight loss much larger than those seen with caloric restriction and increased physical activity,' he said. 'This weight loss has downstream effects on a range of important health issues. This study suggests that we may soon be able to confidently add increased testosterone to that list.'
